Search found 430 matches

by biopearl123
Wed Sep 30, 2020 6:03 pm
Forum: ImetelChat
Topic: ASH abstracts
Replies: 6
Views: 1415

Re: ASH abstracts

I agree it is unlikely they will PR until early Nov re abstract
Tiles. But in the unlikely event of a plenary acceptance they might tell us in Oct. unlikely. bp
by biopearl123
Fri Sep 25, 2020 11:49 pm
Forum: ImetelChat
Topic: A word of support
Replies: 4
Views: 1390

Re: A word of support

Lekola, many thanks for your response, lets hope you are right about the plenary but honestly I don't hold much hope for a plenary this year. I do think Dr. Maskarenhas will get that coveted oral presentation he was denied at EHA. bp
by biopearl123
Fri Sep 25, 2020 1:30 am
Forum: ImetelChat
Topic: A word of support
Replies: 4
Views: 1390

Re: A word of support

Lekola, I failed to mention by fondest dream and that is that Imetelstat is granted a plenary presentation. After all the drug is completely new, has been shown to prolong life in a meaningful way, has shown amazing activity in high transfusion burden MDS and attacks the malignant clone itself. Plen...
by biopearl123
Fri Sep 25, 2020 1:24 am
Forum: ImetelChat
Topic: A word of support
Replies: 4
Views: 1390

Re: A word of support

Hi Lekola, thank you for your kind words of support. I admit that I do tire of the vulgarity and insipid posts that frequent YMB. More than that however is the troubling disinterest in probing areas that fail to support the Geron thesis. When I have posted information that I think is interesting but...
by biopearl123
Thu Sep 24, 2020 12:57 am
Forum: ImetelChat
Topic: Hat tip to PEDMAC2000
Replies: 0
Views: 880

Hat tip to PEDMAC2000

From YMB PEDMAC2000's response to a query of Geron: "While the two seem inter-related, it’s really a matter of closing out a previous study in neuroblastoma, and ongoing dialogue with the European Medicines Agency’s Pediatric Committee (PDCO). As I am sure you are aware, both the EMA and the U.S. Fo...
by biopearl123
Sun Sep 20, 2020 6:46 pm
Forum: ImetelChat
Topic: CD 47 continued again
Replies: 2
Views: 1098

CD 47 continued again

As we continue to assess the potential competition for Imetelstat, the back drop of recent high volume in the market can not be ignored. Friday when the final tally was complete, it was a 35 M volume day, about 10 times the usual daily volume. We have seen recent acquisition activity and large expen...
by biopearl123
Sat Sep 19, 2020 5:01 am
Forum: ImetelChat
Topic: CD 47 continued
Replies: 3
Views: 1557

Re: CD 47 continued

Make that 25 B
by biopearl123
Thu Sep 17, 2020 6:21 pm
Forum: ImetelChat
Topic: CD 47 continued
Replies: 3
Views: 1557

Re: CD 47 continued

Ashah, I wouldn't hold your breath, Gilead just spent a combined 20B on acquisitions. Doubt they have any interest in Geron.
by biopearl123
Thu Sep 17, 2020 7:12 am
Forum: ImetelChat
Topic: CD 47 continued
Replies: 3
Views: 1557

CD 47 continued

There has been a lot of discussion on SA and YMB regarding the Gilead (nee Forty Seven) CD 47/Azacitidine Ib study that has been expanded to include lower risk MDS. I am starting to look a studies to try to asses whether this combination could "leap frog" Imetelstat. I found this in one of Dr. Irvin...
by biopearl123
Wed Sep 16, 2020 9:00 pm
Forum: ImetelChat
Topic: Worth a read...
Replies: 0
Views: 936

Worth a read...

https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.7507 Ryan saw your response on YMB and found it reassuring but not sure it comports with what I am seeing here. Can you help parse this out? Clearly the study cited is a different population than the lower risk MDS Geron PIII but it is notabl...
by biopearl123
Wed Sep 16, 2020 6:09 pm
Forum: ImetelChat
Topic: Notes on Study NCT03248479
Replies: 0
Views: 896

Notes on Study NCT03248479

Magrolimab mono therapy or Magrolimab in combination with Azacitidine in patients with hematological malignancies: Study expanded from 96 patients to to 257. Additional primary end point added: 8 week TI in patients with low risk MDS. Additional thoughts: CD 47 is expressed as disease progress with ...
by biopearl123
Wed Sep 16, 2020 7:42 am
Forum: ImetelChat
Topic: Forty Seven
Replies: 1
Views: 969

Forty Seven

Gilead's recently acquired Forty Seven Pharma magrolimab received Breakthrough Designation (in combination with Azacytidine) from the FDA today based on 1b data. Indication is intermediate, high risk and very high risk MDS. While not quite the same population as low and int risk targeted by Geron, t...
by biopearl123
Mon Sep 14, 2020 6:53 pm
Forum: ImetelChat
Topic: Wainright Presentation
Replies: 1
Views: 1035

Wainright Presentation

Today's (pending as of now) Wainright presentation contains a slide indicating an "unchecked box" relating to the upcoming ASH meeting in December (they will almost certainly be virtual). The usual accept/reject dates for abstracts is early October. Yet we see an indication that Geron data updates a...
by biopearl123
Fri Sep 11, 2020 1:14 am
Forum: ImetelChat
Topic: Two more sites added for MDS study
Replies: 0
Views: 829

Two more sites added for MDS study

A site in Israel and in Germany were added per update today. The primary completion date has not (yet) been altered. Interestingly about 10% of the clinical sites are in Israel when has a particularly high COVID rate right now. We have apparently not yet reached the 50% enrollment mark yet. Dr. Scar...
by biopearl123
Thu Sep 10, 2020 8:29 pm
Forum: ImetelChat
Topic: Recent ATM
Replies: 5
Views: 1613

Re: Recent ATM

To put a point on CKTCs comments, it seems likely that in light of the ready adoption of Luspatercept, at least some impact will be had on enrollment in the PIII MDS study. bp
by biopearl123
Mon Sep 07, 2020 7:40 pm
Forum: ImetelChat
Topic: Recent ATM
Replies: 5
Views: 1613

Re: Recent ATM

Ah, that would explain Dr. Scarlett's careful parse about likely increased acceptance and usage in Europe because of the strictness required in following approval parameter wording there. bp
by biopearl123
Sun Sep 06, 2020 6:52 pm
Forum: ImetelChat
Topic: Recent ATM
Replies: 5
Views: 1613

Re: Recent ATM

CKTC, Good point but since Lus has shown efficacy mainly in RS positive patients (15% or so of MDS), I am not sure docs will be attracted to use Lus in all comers for that reason and may be selective. Also, and I base this on intuition only (not always an accurate commodity), since Lus works "downst...
by biopearl123
Sun Sep 06, 2020 5:58 pm
Forum: ImetelChat
Topic: Recent ATM
Replies: 5
Views: 1613

Recent ATM

There has been a lot of discussion about the recent (surprise) ATM. Speculation has included raising funds for the long promised AML study, a de facto "poison pill" to prevent a hostile take over, acquisition of some synergistic company etc. But these are not normal times. My own opinion is pretty s...
by biopearl123
Sat Sep 05, 2020 11:27 pm
Forum: ImetelChat
Topic: Orphan being discussed AML/MDS/JMML
Replies: 9
Views: 2114

Re: Orphan being discussed AML/MDS/JMML

CKTC and Bill, thank you for clarifying. The PDCO process seems to be a little more public than the actual approval process. For example, I don't think we knew that orphan designation was under discussion until the PR, I imagine the same would be true for MA, if it is even under any consideration at...
by biopearl123
Fri Sep 04, 2020 5:57 pm
Forum: ImetelChat
Topic: Orphan being discussed AML/MDS/JMML
Replies: 9
Views: 2114

Re: Orphan being discussed AML/MDS/JMML

Incidence of MDS in pediatric age group: 1-4 per million. Population of Europe: 741 million. High end estimate of pediatric cases 4 x 741= 2,964. Low end estimate of cases 741. Orphan indeed. bp